fda warning compounding semaglutide september 2025 Out of Shortage, Into Controversy: The Fight Over GLP-1 FDA Sends Warning Letters to

The goal is to provide reliable, evidence-based information without any unnecessary hype

While hyperkalaemia occurred more frequently with finerenone than with placebo, this was often mild or moderate and resulted in few drug discontinuations (2.3% vs 0.9%, respectively), despite study participants also being on maximum-tolerated RAS inhibitor therapy

The critical variable is concentration

Davies MJ, Aroda VR, Collins BS et al (2022) Management of hyperglycemia in type 2 diabetes, 2022

If it was left out in high heat above 77F86F depending on your insulin type even one hour can be enough to cause damage

Children (519) 2022: about 1 in 5 overweight